DEA EXTENDS TELEHEALTH FLEXIBILITIES UNTIL

NOVEMBER 11, 2023

The ability to prescribe controlled substances based on telehealth patient visits was set to expire when the COVID-19 Public Health Emergency ended on Thursday, May 11th. The U.S. Drug Enforcement Administration (DEA) initially issued two proposed rules establishing new policies for controlled substance prescriptions based on telehealth visits, one for buprenorphine and one for other controlled substances. After receiving more than 38,000 comment letters, however, the DEA has decided to extend [federalregister. gov] the same policies that have been in place during COVID for an additional 6 months, until November 11, 2023. https://www.federalregister.gov/ documents/2023/05/10/2023-09936/temporaryextension-of-covid-19-telemedicine-flexibilitiesfor-prescription-of-controlled